SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IPIC
IPIC 0.0001000+899.9%Aug 15 3:35 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (539)8/12/1997 10:23:00 AM
From: Biomaven   of 1359
 
Miljenko:

I'd like to address the issue of the imbalance of mild stroke patients between the placebo and drug groups. You imply that this is somehow evidence of manipulation, deception or just plain incompetence.

To my mind, this imbalance is a good indication that there was _no_ manipulation/deception in the trial. The last thing the company would have wanted was to have a disproportionate number of mild cases (who get better anyhow) in the placebo group. If there had been a disproportionate number of _severe_ cases in the placebo group, then you (perhaps) would have been justified in claiming something fishy was going on.

So how did this imbalance happen? I think it is most likely that the statistical trial gods were just unkind. As has been pointed out, if you assign patients randomly, you are not _guaranteed_ an even distribution of characteristics between the two groups.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News